Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)

US National Institutes of Health (NIH) grant open #PAR-25-297

Response due Nov 05, 2027 · 00:00 UTC

Summary

The National Institutes of Health (NIH) is funding research under the Alzheimer's Drug-Development Program via a U01 cooperative agreement mechanism. Clinical trials are optional under this funding opportunity. The program aims to advance drug development efforts targeting Alzheimer's disease. The opportunity is open for a multi-year window spanning late 2024 through late 2027.

What they want

Technical requirements

Proposed research must be relevant to Alzheimer's drug development
Clinical trial component is optional but must comply with NIH clinical trial policies if included
Must conform to U01 cooperative agreement terms and conditions

How they evaluate

Submission: Grants.gov federal grants portal (PAR-25-297)

Risks & flags

No dollar value or award ceiling disclosed, making competitive benchmarking difficult
Multi-year open window (nearly 3 years) with rolling submissions may favor applicants with established NIH relationships and prior U01 experience

Market context

inferred from NAICS

Professional, Scientific & Technical Services

NAICS 541714

US market size: $2.0T
Typical award: $25K – $50M

Typical buyers

All federal civilianDoDStates

Commonly required

8(a)WOSBSDVOSBPE/PMP

Sector-level estimate — full code lookup not yet in catalog.

Alzheimer's Drug-Development Program (U01 …

Due Nov 05

Onboard ↗